Ann: City of Hope Professor Jianjun Chen joins Race's SAB, page-151

Great explanation!

I think of it as PD-1 removes a protective shield that cancer uses to evade detection by the immune system. PD-1 brings down the shield and puts up a red flag, allowing the immune system to locate and destroy the cancer.

unfortunately PD-1 is effective on approximately 15% of the time. meaning that 85% it is ineffective, not great odds.

Race is testing research that suggests, Zantrene (a first in class, best in class - FTO inhibitor) lets the immune target and kill the cancer, bringing down the shied even when PD-1's red flag does not work. My readings suggest that CD8+ is indirectly regulated by FTO inhibition and thus the connection to T-cells.

I think it is simple enough to work out the commercial opportunity, if PD-1 efficacy can be improved by even 1%, 5%, or 10% by an FTO inhibitor.